3 results match your criteria Pulmonary Fibrosis Interstitial Nonidiopathic

  • Page 1 of 1

Clinical implications of telomere dysfunction in lung fibrosis.

Curr Opin Pulm Med 2018 09;24(5):440-444

Service de Pneumologie, Centre constitutif du centre de référence, des Maladies Pulmonaires Rares, DHU FIRE, Hôpital Bichat, APHP, INSERM, Unité 1152, LabEx Inflamex, Paris, France.

Purpose Of Review: Telomere attrition has been proposed as one of the aging hallmarks in pulmonary fibrosis. Telomere shortening and telomerase gene mutations have been widely evaluated in recent years. Reduced telomere length may be identified in a quarter of patients with sporadic idiopathic pulmonary fibrosis (IPF) and half of those cases with family aggregation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MCP.0000000000000506DOI Listing
September 2018
11 Reads

Unclassifiable interstitial lung disease: from phenotyping to possible treatments.

Curr Opin Pulm Med 2018 09;24(5):461-468

Department of Medicine, University of British Columbia.

Purpose Of Review: Accurate diagnosis of interstitial lung diseases (ILDs) can be challenging, and a substantial percentage of ILD patients remain unclassifiable even after thorough assessment by an experienced multidisciplinary team. In this review, we summarize the recent literature on the definition, prevalence, diagnosis, treatment, and prognosis of unclassifiable ILD, and also discuss important current issues and provide future perspectives on the classification of ILD.

Recent Findings: Approximately 12% of patients with ILD are considered unclassifiable, with large variability across previous studies that is in part secondary to inconsistent definitions of unclassifiable ILD and other ILD subtypes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MCP.0000000000000509DOI Listing
September 2018
43 Reads

Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias: the time is now (?).

Curr Opin Pulm Med 2017 09;23(5):418-425

aCenter for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Critical Care Medicine, Thoraxklinik, University of Heidelberg, Heidelberg bMember of the German Center for Lung Research cDepartment of Internal Medicine V, Comprehensive Pneumology Center, Asklepios Fachkliniken, University of Munich, Munich, Bavaria, Germany.

Purpose Of Review: Therapeutic advances in the management of idiopathic pulmonary fibrosis (IPF) has led to improved outcomes with the use of the antifibrotic agents pirfenidone and nintedanib, with a number of randomized studies demonstrating benefits in slowing disease progression in IPF. However, treatment of other fibrosing interstitial lung diseases (ILD) remains challenging.

Recent Findings: Observational and uncontrolled studies investigating pirfenidone and nintedanib in non-IPF ILDs suggest potential benefits, although the data is weak. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MCP.0000000000000408DOI Listing
September 2017
15 Reads
  • Page 1 of 1